Natera, Inc. (NTRA): Capital Expenditures
$106.19M
Year ended 2025-12-31
$144.04M
Trailing 12 months to 2026-06-30
+30.6%
3-year compound annual growth
+40.2%
5-year compound annual growth
+29.8%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $106.19M | +59.9% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $66.42M | +69.5% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $39.20M | -17.8% | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | $47.70M | +16.2% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $41.03M | +109.3% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $19.60M | +294.6% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $4.97M | +28.0% | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $3.88M | -60.7% | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $9.87M | -57.4% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $23.14M | +194.7% | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | $7.85M | -21.1% | 2018-03-15, From 2015-01-01 |
| 2014-12-31 | $9.96M | +20.8% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $8.24M | n/a | 2016-03-24, From 2013-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Natera, Inc. (NTRA) | 2025-12-31 | $106.19M | +59.9% |
| Fortrea Holdings Inc. (FTRE) | 2025-12-31 | $25.20M | -1.2% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $48.31M | +37.7% |
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $16.26M | +92.6% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $9.68M | -14.3% |
| Quest Diagnostics Inc (DGX) | 2025-12-31 | $527.00M | +24.0% |
| Labcorp Holdings Inc. (LH) | 2025-12-31 | $434.50M | -11.3% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $36.02M | +27.2% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $22.57M | -44.0% |
Compare NTRA, FTRE, GH, CAI side by side · Screen every company in Services-Medical Laboratories ↗